IMDX has surged 158% over the past year and is trading at a new two-year high. ・Shares maintain a 100% “Buy” opinion from ...

The average one-year price target for Insight Molecular Diagnostics (NasdaqCM:IMDX) has been revised to $7.14 / share. This ...

The "Molecular Diagnostics for Cancer – Markets, Strategies and Trends. Forecasts by Cancer Type, Including Companion Dx and by Country with Executive and Consultant Guides and COVID-19 Pandemic ...

Molecular diagnostics is becoming a driving force in drug development. Applications have spread from identifying infections to include screening for cancer, hepatitis, and a variety of genetic ...

Clinical Utility of Pharmacogenomics and Genetic Testing Remains an Issue Through rapid advances in research and clinical applications, molecular diagnostics has grown from a genomic and proteomic ...

Analysts are estimating that Co-Diagnostics will report an earnings per share (EPS) of $-0.19. Anticipation surrounds ...

Insight Molecular Diagnostics Inc. is rated Hold due to upcoming catalysts & pending FDA submission for GraftAssureDx. Read ...

Investments in precision medicine, expanding healthcare infrastructure, and rising infectious disease burden fuel market ...

MEMPHIS, Tenn.--(BUSINESS WIRE)--Spesana, the developer of a novel electronic operating system to unify EMRs, and Biodesix Inc. (NSDQ: BDSX), a leading data-driven diagnostic solutions company with a ...

The consensus estimate for Q3 2025 revenue is $0.28 million, and the earnings are expected to come in at -$0.21 per share.